AstraZeneca received more funding
As the race for a viable COVID-19 vaccine intensifies, companies do their best to make it all happen. But sometimes things don’t go as planned. So it seems to be the case of Johnson & Johnson.
The giant announced that it has temporarily halted the #COVID-19 #vaccine candidate clinical trials because one of the participants got sick.
To review and evaluate the participants, an independent company has been hired. Also, the company’s clinical and safety physicians are being monitored. The company didn't provide further information about the matter due to privacy concerns.
However, J&J is not the first company to halt its clinical trial. In September, AstraZeneca paused the late-stage trials of its vaccine developed with the University of Oxford, after a British participant got sick. But the company overcame the incident, and now, its antibody treatment will be funded with $486 million. The pharma company will receive the money from the Trump Administration’s Operation Warp Speed to provide 100,000 doses. Under the agreement, the government could purchase as much as 1 million doses.
“This agreement with the US Government will help accelerate the development of our long-acting antibody combination, which has the potential to provide immediate and long-lasting effect in both preventing and treating COVID-19 infections. We will be evaluating the LAAB combination in different settings from prophylaxis, to outpatient treatment to hospitalization, with a focus on helping the most vulnerable people,” read CEO Pascal Soriot’s statement.
Following the news, during pre-market trading, JnJ stock price dropped 1.56%. AstraZeneca is trading 0.85% lower.
Read here about Eli Lilly and Gilead!
Sources: thestreet.com, finance.yahoo.com
This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation or the particular needs of any recipient.
You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.
This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent. Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of za.capex.com